Alnylam plans $250m investment in Norton manufacturing facility, US [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
This is claimed to become the first fully dedicated small-interfering RNA (siRNA) enzymatic-ligation manufacturing facility. The facility expansion is intended to increase capacity, lower production expenses, and enable support for future medicine launches from the company's development pipeline. As part of this, the company's next-generation, scalable enzymatic ligation manufacturing platform, known as siRELIS, has been accepted into the US Food and Drug Administration's Emerging Technology Program. The programme is expected to facilitate discussions with global health authorities regarding manufacturing approaches for oligonucleotide-based medicines. This acceptance comes after pilot-scale production of zilebesiran, which is under investigation for decreasing the risk of major adverse cardiovascular events in hypertension patients, and nucresiran, being developed for transthyretin-mediated amyloidosis (ATTR). The siRELIS platform enables RNAi therapeutic manufacturing wit
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues [Yahoo! Finance]Yahoo! Finance
- Cambridge biotech will invest $250M in Mass. production facility, add jobs [Yahoo! Finance]Yahoo! Finance
- Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics [Yahoo! Finance]Yahoo! Finance
- Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi TherapeuticsBusiness Wire
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Leerink Partners from $370.00 to $351.00. They now have a "market perform" rating on the stock.MarketBeat
ALNY
Earnings
- 10/30/25 - Beat
ALNY
Sec Filings
- 12/11/25 - Form 8-K
- 12/3/25 - Form 8-K
- 12/1/25 - Form 4
- ALNY's page on the SEC website